ReviewDrugs in context2020
Acute bacterial sinusitis in children: an updated review.
Review in Drugs in context, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Treatment of sinusitis in children: an Italian intersociety consensus (SIPPS-SIP-SITIP-FIMP-SIAIP-SIMRI-SIM-FIMMG).Italian journal of pediatrics · 2025Pooled it
- Review
- Frequency and clinical characteristics of hydroxychloroquine-induced pigmentation in Japanese paediatric patients: a retrospective cohort study.Rheumatology international · 2026Article
- Occult invasive group A streptococcal infection with rapid progression to pediatric intraorbital abscess: a case report.BMC pediatrics · 2026Article
- The future of severe acute respiratory syndrome-cornavirus and coronavirus disease.World journal of pediatrics : WJP · 2026Article
- Imaging characteristics and clinical correlations of orbital infections in pediatric sinusitis.Head & face medicine · 2026Article
- Paediatric Otorhinolaryngological Disorders: Early Detection and Management Strategies.Cureus · 2025Article
- Metatranscriptomic profiling reveals pathogen and host response signatures of pediatric acute sinusitis and upper respiratory infection.Genome medicine · 2025Article
- Role of IFN-γ and TGF-β in the Pathophysiology of Chronic Sinusitis :.Galen medical journal · 2025Article
- Article
- Pediatric Odontogenic Sinusitis: A Systematic Review.Journal of clinical medicine · 2024Review
- Article
- A Narrative Review of Recent Antibiotic Prescribing Practices in Ambulatory Care in Tanzania: Findings and Implications.Medicina (Kaunas, Lithuania) · 2023Review
- A Narrative Review of Antibiotic Prescribing Practices in Primary Care Settings in South Africa and Potential Ways Forward to Reduce Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2023Article
- COVID-19 Co-Infection May Promote Development of Sinusitis Complication in Children.Children (Basel, Switzerland) · 2022Article
- Antibiotic stewardship programmes had a low impact on prescribing for acute respiratory tract infections in children.Acta paediatrica (Oslo, Norway : 1992) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the pediatric age group, approximately 7.5% of upper respiratory tract infections (URIs) are complicated by acute bacterial sinusitis (ABS). Despite its prevalence, ABS is often overlooked in young children. The diagnosis and management present unique challenges in primary care. This is an updated narrative review on the evaluation, diagnosis, and management of ABS.
methodsA PubMed search was performed using the key term 'acute sinusitis'. The search strategy included clinical trials, meta-analyses, randomized controlled trials, observational studies, and reviews. The search was restricted to the English literature and children.
results
conclusionData from high-quality studies on the management of ABS are limited. The present consensus is that amoxicillin-clavulanate, at a standard dose of 45 mg/kg/day orally, is the drug of choice for most cases of uncomplicated ABS in children in whom antibacterial resistance is not suspected. Alternatively, oral amoxicillin 90 mg/kg/day can be administered. For those with severe ABS or uncomplicated acute sinusitis who are at risk for severe disease or antibiotic resistance, oral high-dose amoxicillin-clavulanate (90 mg/kg/day) is the drug of choice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.